European Continuing Education College



Similar documents
European Continuing Education College

Introduction to pharmaceutical technology

OOS investigations in a GMP environment

Main Conference Agenda

Drug Delivery Systems III

EXIGENCIA DE ESTUDIOS DE BIOEQUIVALENCIA A TRAVÉS DE METODOS IN VITRO

Introduction to Enteris BioPharma

Overview of Dissolution for BA/BE

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

QUALITY, SAFETY AND EFICACY ASSESSOR

Bundesinstitut für Arzneimittel und Medizinprodukte. Dissolution Testing. Analytik,Methodenentwicklung, Bioäquivalenz SAQ. Olten, 25.

Decommissioning of nuclear facilities

Mostly, for a conventional dosage form the dosing i ntervals of the drug are much less than the drug half life leads to numerous limitations.

Public Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no:

A masterclass in professional trading

Asian Journal of Research in Biological and Pharmaceutical Sciences Journal home page:

HIGH-TONED CONFERENCE

Guidance for Industry

Drug Safety of Stem Cells and other Novel Therapeutics

Food, Medicine and Health Care Administration and Control Authority

Electronic GMP Systems

Alharith Hassan. Q 10 Method of Shelf-life estimation. Methods of Chemical stabilisation 11/20/2015

Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches

Absorption of Drugs. Transport of a drug from the GI tract

Guideline on Process Validation

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no:

IHLM Certificate In Healthcare Operations Management

Corso di Laurea Magistrale in Farmacia

Method Development and Validation for Particle Size and Shape Measurements

Raising Finance in the Bond Market

A Preliminary Proposal for a Pharmaceutical Engineering Graduate Program

The Science Education System in Oxford and the UK. David Andrews

M.Sc. in Nano Technology with specialisation in Nano Biotechnology

PRODUCT DEVELOPMENT GUIDE

REVIEW: IN-VITRO DRUG RELEASE CHARACTERIZATION MODELS Gautam Singhvi, Mahaveer Singh

Monitoring. Compliant and Reasonable. 5-6 May 2015, Berlin, Germany

Generic drugs are copies of innovator drug products

Masters Learning mode (Форма обучения)

Fachgruppe Drug Delivery

Oil & Gas Talent Management Workshop

Manchester Pharmacy School.

Managing the EU Policy Cycle: A Comprehensive One-Week Course on EU Decision-Making in Practice

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Bioequivalence Testing, using the Dissolution Profile

A FDA Perspective on Nanomedicine Current Initiatives in the US

Hygienic Engineering and Contamination Control

Channel Islands Conference June Radisson Blu Waterfront Hotel, Jersey

IT System and Data Security: New Developments in Cloud Computing, Virtualisation and GMP Compliance

Guidance for Industry

Revision of The Dissolution Procedure: Development and Validation 1092

Academic Calendar for Faculty

Computerised Systems in Analytical Laboratories

A Stability Program for the Distribution of Drug Products

Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA Phone: Fax:

Guidance for Industry

MARITIME LAW AND MARINE INSURANCE CLAIMS

Certificate In Healthcare Leadership And Management

UNIVERSITY OF PARMA INTERDEPARTMENTAL CENTRE FOR INNOVATION IN HEALTH PRODUCTS, BIOPHARMANET-TEC

Performance Management in Public Sector Organisations: The Contribution of the CAF

Journal of Chemical and Pharmaceutical Research

Sublingual drug delivery system

GUIDANCE NOTES TO COMPANIES ON HEARINGS BEFORE AND WRITTEN REPRESENTATIONS TO THE ADVISORY BOARD ON THE REGISTRATION OF HOMEOPATHIC PRODUCTS

Salary Survey Domestic, International Salary Survey and Country Cost Analysis

Annex 7 Guidelines on pre-approval inspections

Working with ICH Quality Guidelines - the Canadian Perspective

MSc in Physics Research For students entering in 2006

POLYOX. Application Data

Guideline on stability testing for applications for variations to a marketing authorisation

Pharmaceutical Physical Characterization: Surface Area and Porosity

The importance of normalisation when comparing tablet properties

Celebrating 25 Years of Trade Facilitation through Expertise and Innovation

Guidance for Industry

Working Group Meeting of the

QbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance

FX OPTION PERFORMANCE: LONG TERM ANOMALIES, OPPORTUNITIES AND HEDGING STRATEGIES BY JESSICA JAMES

Internal and external AUDIT of the EU funded programmes and projects

PHARMACEUTICAL DEVELOPMENT

Report of Step 3 event towards degree accreditation; Master of Pharmacy degree of the University of Sunderland, SEGi University College, May 2010

A MULTIVARIATE TEST FOR SIMILARITY OF TWO DISSOLUTION PROFILES

Lean Strategies for Laboratory Testing

Annex 6. Guidance on variations to a prequalified product dossier. Preface

Colours in Pharmaceutical Products

Research needs in pharmaceutical excipients: implications of a global supply chain

THE PHARMACEUTICAL INDUSTRY

Directly compressed mini-tablets coated in a solid-wall pan for sustained drug release

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.

Continuous Granulation and Drying

20-21 May 2015, Lisbon, Portugal. Highlights. Speakers:

Management, Supply and Quality Assurance of Clinical Trials

Transcription:

Design and Development of Conventional and Modified Release Oral Drug Delivery Systems Three Day Intensive Course for Managers, Scientists and Technicians with the Emphasis on the Principles of Oral Drug Development from Preformulation through to Regulatory Requirements Holiday Inn Hotel, Oxford Circus, London, UK 14th, 15th and 16th October 2015 Course Background Solid oral dosage forms, whether produced as conventional or extended release systems, are the major dosage form of the Pharmaceutical Industry. Although conventional and extended release systems are frequently discussed separately, there are many elements common to the two types of dosage form. The purpose of this course is to provide the common links between the systems. The starting point for any decision as to the type of dosage form to be produced is a thorough understanding of the physico-chemical and biological properties of the drug. If some of these properties are unfavourable, for example, solubility, there may be a need to alter the properties of the drug at an early stage. All dosage forms will require the use of excipients in their production and an understanding of the behaviour of these materials during processing is essential for successful formulation. Although some of the course will be directed solely to an understanding of extended release systems, the majority of the lectures will emphasise the common ground in the realisation that formulators will be required to work on both types of system. Course Objectives The principle objectives of the course are to provide an up-to-date understanding of the principles of the formulation of solid dosage forms from the preformulation stage through to marketing acceptance. The common links between the different types of dosage forms will be emphasised. The course will be taught in such a way as to provide both theoretical and practical aspects of the subject. Who Should Attend There are no prerequisites of knowledge or expertise for participants attending the course. Individuals who require a knowledge of the many facets of the formulation of solid oral dosage forms will benefit from attendance. The course will be most suited to those working in pharmaceutical formulation, research and development, manufacturing, quality control and assurance, validation of pharmaceutical processes, technology transfer and marketing. The course will also benefit other individuals working in regulatory affairs, licensing and project planning.

Course Outline Biopharmaceutics in Pre-Development Understanding absorption; biopharmaceutical classification system; models for studying drug absorption from the G.I. tract, particularly cell based models; physico-chemical properties of drugs affecting bioavailability; formulation approaches to overcoming poor bioavailability. Poorly Soluble Drugs Methods for increasing dissolution rates; particle size, wettability; ph effects; salt formation; metastable polymorphic forms; glassy state. Advantages and disadvantages of the following techniques; solid dispersions; solvent deposition; cyclodextrins; co-mixing; liquid fill capsules Excipients Review of available excipients for conventional and extended release, their properties and the rationale for selection; current trends in excipients and formulation; direct compression materials; improvements in compaction characteristics. Basic Principles of Extended Release Suitability of drug candidates for formulation as extended release delivery systems with emphasis on the importance of drug physico-chemical properties; technical and dosage form design considerations in the formulation of extended release systems; fabrication options for single and multiple unit oral systems. Mechanisms of Drug Release Particular emphasis on extended release products; diffusion control across membranes (reservoir), through inert matrices (monolithic), by matrix erosion, across hydrophilic gels; swellable systems (hydrogels), swelling controlled and relaxation dependent diffusion. Assessment and Evaluation of Solid Dosage Forms In vitro dissolution testing and its relevance in quality assurance and bioavailability; in vivo release - non invasive methodologies; in vitro/in vivo correlations. Polymer Film Formulation Advances in techniques and formulations; polymer properties; enteric formulations; systems for extended / controlled release and targeting; new functional and non-functional systems. Case Studies/Data Analysis Participation in Group workshops. Lecturers John Collett PhD DSc FRPharmS (Course Director) Professor Collett is Emeritus Professor of Drug Delivery in The School of Pharmacy and Pharmaceutical Sciences at the University of Manchester. He is also CSO at Quay Pharmaceuticals. He has extensive research experience in the UK and USA and is a leading authority on polymeric drug delivery. He collaborates extensively with pharmaceutical companies in this field. John Fell B.Sc., Ph.D., M.R.Pharm.S Dr Fell is a Emeritus Reader in Pharmacy at the University of Manchester and is well known for his work in tableting. He also has published widely in the areas of the wetting and surface energetics of solids and the imaging and in vivo behaviour of solid dosage forms.

Lecturers James Ford B.Sc., Ph.D., M.R.Pharm.S Professor Ford is Professor of Pharmaceutics at Liverpool John Moores University. His research interests include controlled oral drug delivery via matrices and pellets, the interactions between hydrophilic polymers and water, modifications of the solid state to improve compaction properties of drugs and excipients and pharmaceutical aspects of thermal analysis. Professor Ford has published widely in these areas including, with Dr Timmins, a standard text on thermal analysis. He collaborates widely with pharmaceutical companies. Hiep Huatan Ph.D., B.Pharm. Dr Huatan is an independent Consultant and was formerly a Senior Principal Scientist at Pfizer and was Team Leader of the Controlled Release Group based in Sandwich, UK. He was responsible for the development of Pfizer s controlled release dosage forms for both NCE s and product enhancement candidates. He has published widely in the area of controlled release and published more than 30 papers and abstracts over the last 5 years. Dr Huatan has had considerable experience at Pfizer in pre-formulation and biopharmaceutical areas for both human and veterinary health. Chris Moreton B.Pharm., M.Sc., M.R.Pharm.S., Inst. Pkg (Dip)., Ph.D. Dr Moreton is an Independent Consultant and was formerly Vice President, Pharmaceutical Sciences at Idenix Pharmaceuticals, Cambridge, USA and was responsible for all formulation activities from preclinical safety studies through preformulation, formulation design and development, scale-up, clinical supply manufacture and technology transfer to the commercial manufacturing sites. Dr Moreton has over 25 years industrial experience at Pfizer Central Research, Sterling Winthrop R & D, ACO in Sweden and more recently at Penwest both in the UK and the USA At Penwest Pharmaceuticals he worked with excipients covering technical service and support, R & D and QA/QC for the drug delivery business. Dr Moreton is a member of the USP Expert Working Group on Excipient Test Methods. He is currently Chairman of the IPEC-Americas (International Pharmaceutical Excipients Council of the Americas) and a member of the Drug Product Technical Committee (DPTC) of the Product Quality Research Institute (PQRI). Dr Moreton has special expertise in the formulation of solid dosage forms. Marcel Cimpan B.Eng. Mr Cimpan is Technical Manager, Europe, Middle East and Africa for Colorcon Ltd. He is responsible for technical aspects of the range of Colorcon excipients. Marina Levina MSc., Ph.D. Dr Levina is Global Technical Manager, Excipients at Colorcon Ltd. and is responsible for all technical aspects of the range of Colorcon excipients. She has experience in the production of tablets by conventional and by ultrasound assisted compaction and with the development of solid oral dose formulations for both immediate release and sustained release applications

Fees and Registration The participation fee is 1595.00 (exclusive of VAT). Places are strictly limited and therefore applications will be accepted on a first come basis. Under UK law all applications are subject to Value Added Tax (VAT) irrespective of the country of origin of participants. Most VAT registered companies/organisations can reclaim this tax. The fee includes full personal participation, extensive bound course notes, luncheons and light refreshments, on all days of the Course. Dinner at night is not included. Cancellations cannot be accepted less than 14 days prior to the start of the Course, but substitutions may be made at any time. The Course language will be English. An approved Certificate of Attendance will be given to each participant at the end of the Course. Timing of the Course Registration will be at 8.45am on Wednesday 14th October and the Course will commence promptly at 9.00am. The Course will finish at about 17.00 on Friday 16th October. The Course will end at about 18.00 on each of the first two days.

ECEC - Registration Form Course - Design and Development of Conventional and Modified Release Oral Drug Delivery Systems Please fill in the following details to apply for a place. No payment is necessary now. When filling in the form, fields marked with an asterix (*) are compulsory. Your form will not be submitted if they are left blank. Personal Details First name: * Surname: * Organisation: Job title: Address: * Post/zip code: * Telephone no: Extension: Fax no: Email address: * I wish/do not wish to receive future mailings from ECEC about forthcoming courses. (Please note, we do not disclose your email address to any third party) Accommodation Accommodation will be at the: Holiday Inn Hotel, Oxford Circus, London, UK Room Rates: Single Room - Bed & Breakfast per person, per night 185.00 Twin Room - Bed & Breakfast per person, per night 220.00 Double Room - Bed & Breakfast per person, per night 220.00 Choose accommodation Type: I don t want accommodation I would like a Single Room - Bed & Breakfast I would like a Twin Room - Bed & Breakfast I would like a Double Room - Bed & Breakfast Choose which days: Tuesday 13th October 2015 Wednesday14th October 2015 Thursday 15th October 2015 Friday 16th October 2015 Other nights (please specify): * Please note: Under UK law all applications are subject to Value Added Tax (VAT), irrespective of the country of origin of the Participant PLEASE FAX THIS COMPLETED FORM TO +44 (0)151 211 1860